INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
VE

Venker Eric

Director, Chief Executive OfficerCIK 0001801917

EDGAR filingsOpen in network
Disclosed transactions12
Buys / sells0 / 6
Max Insider Score23
Connections2with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
14
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$7.32M
200.0K sh
Oct 28, 2026Oct 30, 2026
traded Oct 28, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Roivant Sciences Ltd.President & Immunovant CEO · Apr 22, 2026
  • Insider ofevidence
    Immunovant, Inc.Director, Chief Executive Officer · Apr 9, 2026
7
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL
$501K
14.1K sh
Oct 20, 2026
Oct 22, 2026
traded Oct 20, 2026
+2d
SEC FORM 4

Evidence

14
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$6.52M
185.9K sh
Oct 20, 2026Oct 22, 2026
traded Oct 20, 2026
+2dSEC FORM 4

Evidence

0
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Option exercise · 10b5-1 plan
M—
200.0K sh
Jun 24, 2026Jun 26, 2026
traded Jun 24, 2026
+2dSEC FORM 4

Evidence

5
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Option exercise · 10b5-1 plan
M$770K
200.0K sh
Jun 24, 2026Jun 26, 2026
traded Jun 24, 2026
+2dSEC FORM 4

Evidence

14
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$5.08M
153.8K sh
Jun 24, 2026Jun 26, 2026
traded Jun 24, 2026
+2dSEC FORM 4

Evidence

10
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$1.55M
46.2K sh
Jun 24, 2026Jun 26, 2026
traded Jun 24, 2026
+2dSEC FORM 4

Evidence

9
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Option exercise · 10b5-1 plan
M$770K
200.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

23
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$5.92M
200.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

0
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Option exercise · 10b5-1 plan
M—
200.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
VE
Venker EricDirector, Chief Executive Officer
IMVTImmunovant, Inc.
Grant or award
A—
336.0K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

21
VE
Venker EricDirector, Chief Executive Officer
IMVTImmunovant, Inc.
Grant or award
A—
232.3K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence